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More than 25 million Americans or 8.3% of the population have diabetes mellitus of which approximately 95% of diagnosed cases are type 2 diabetes. 1 Between 1990 and 2010, the number of new cases of diabetes has almost tripled in the U.S. and the Centers for Disease Control projects that 1 in 3 Americans will have diabetes by 2050 if this trend continues. The presence of type 2 diabetes increases the risk of microvascular complications such as retinopathy and nephropathy, and macrovascular disease most notably atherosclerotic coronary artery disease (CAD). Indeed, CAD-related death remains the primary cause of mortality in patients with type 2 diabetes even on standard glucose control. 1 However, more intensive glucose control is not associated with reduced CAD risk and may even increase mortality, 2 therefore there remains a critical need to determine novel adjunct therapy to standard glycemic control that will reduce vascular risk in patients with type 2 diabetes.
In 1996, a seminal paper by Ishii et al. 3 demonstrated that selective inhibition of the isoform of protein kinase C (PKC ), a serine/threonine protein kinase that becomes activated in nutrient excess states such as hyperglycemia, resulted in significant improvement in retinal and glomerular microvascular function in diabetic rats in the absence of any alterations in glycemia or blood pressure. This study elucidated PKC as a potential novel target in diabetes-related vascular complications and identified increased tissue concentrations of diacylglcyerol (DAG), likely as a result of excess de novo synthesis in hyperglycemia, as the primary activator of PKC in rats. Consistent with this, DAG concentration and PKC activity are increased in aortas of obese insulin resistant rats and are associated with reduced insulin-stimulated activation of protein kinase B (Akt). 4 Akt is a serine/threonine kinase regulated by upstream phosphatidylinositol 3 kinase (PI3K) that directly phosphorylates nitric oxide synthase (eNOS) at serine 1177 (eNOS ser1177 ), resulting in eNOS activation and nitric oxide (NO) synthesis. critical need to determine novel adjunct therapy to standard glycemic control that at t w w wi ill l l r re redu du duce ce c vascular risk in patients with type 2 diabetes. I I In 1 1 199 99 996, a a a s s sem e inal paper by Ishii et al. 3 d d dem em emonstrated that t s selec ec cti ti tiv ve inhibition of the s sof f fo orm of pro ote tein in i k kin inas ase C C (P (P (PKC KC ) ), ), a a a s se erin ne/ /t thre eon n nine e e pr pr pro ot ote ei in n k k kin n nase e t th ha at t be be beco come me mes ac act tiv va vate ted d in i nu nutr tr rie ie ient nt nt e e exc xc xce es ess s s st stat at tes es es s suc uc ch h h as s h h hyp yp yper er ergl glyc yc cem em mia ia ia, , , re re resu su sult lted ed e i in n si si sign gn gnif if ific ican an ant t t im im mpr pr prov ov o em em emen en ent t t in in in r r re et etin in nal al al a a and nd d glomerular m m mic ic icro ro rova va vasc sc scul ul ula ar f f fun un unct ctio io ion n n in in in d d dia ia iabe be beti ti t c c c ra ra rats ts t i i in n n th the e e ab ab abse se senc nc nce e e of of f a a any ny ny a a alt lt lter er e at at atio io ons ns ns i in n n glycemia Interestingly, the reduction in insulin-stimulated Akt phosphorylation and NO bioavailability in aortas of obese insulin resistant rats are partly reversed after 2 weeks of PKC inhibition. 4 Additionally, 2 weeks of PKC blockade improves NO-mediated endothelium-dependent vasodilation (EDV) of mesenteric arteries in streptozotocin-induced diabetic rats. 5 Consistent with the animal data, overexpression of PKC 1 or 2 in cultured endothelial cells demonstrate a decrease in insulin-mediated Akt phosphorylation and eNOS expression 4 , and exposure of bovine aortic endothelial cells to high glucose for 24 hours results in reductions in insulinstimulated tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1), phosphorylation of Akt and eNOS and NO production. 6 Taken together, these studies provide strong in vivo and in vitro evidence that increased endothelial PKC activity in diabetes and/or hyperglycemia results in "endothelial insulin resistance" phenotype characterized by impairments in the insulinmediated IRS-1/Akt/eNOS pathway and EDV. Thus, these data support the idea that PKC inhibition may be a novel clinical strategy to reverse endothelial insulin resistance and dysfunction in humans with diabetes.
However, results from several large randomized multicenter trials investigating the efficacy of the selective PKC inhibitor ruboxastaurin on diabetic retinopathy and nephropathy have been equivocal. 7 Also, several small clinical studies in humans testing the efficacy of short-term PKC inhibition on peripheral vascular EDV in humans have been disappointing.
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Howe weve ver, r, r res esul ults ts f fro rom m se seve vera ral la la l rg rge e ra ra d nd ndom omiz ized ed m mul ul lti tice cent nter er t tri i rial als s in inve vest stig igat at tin ing g the with Type 2 diabetes. 10 However, the differences between groups were largely the result of a decline in EDV in the placebo group rather than a treatment effect of ruboxastaurin in the patients with diabetes. Collectively, the available evidence in humans to date suggest a lack of efficacy of PKC inhibition on microvascular disease outcomes and vascular EDV in patients with type 2 diabetes.
In the current issue of Circulation, Tabit et al. 11 describe an interesting cross-sectional study where they compared basal and insulin-mediated alterations in eNOS activation before and after ex vivo PKC blockade in venous endothelial cells that were freshly isolated from patients with type 2 diabetes and healthy controls. They report a paradoxical higher basal expression of phosphorylated eNOS ser1177 in endothelial cells from patients with type 2 diabetes compared with healthy controls. The finding of increased phosphorylation of eNOS Ser1177 in the absence of differences in total eNOS protein expression also has been observed in obese humans. 12 This observation may represent a compensatory upregulation of eNOS phosphorylation in the setting of excessive superoxide production from increased eNOS uncoupling and/or NADPH oxidase activity in diabetes and obesity that results in reduced NO bioavailability and accumulation of nitrotyrosine in the vascular wall. In a novel translational approach, the authors exposed the isolated endothelial cells to insulin before fixation, and this resulted in a reduction in phosphorylated eNOS Ser1177 in cells from the diabetic patients but an increase in phosphorylated eNOS Ser1177 in the healthy control cells suggestive of insulin resistance in endothelial cells of diabetics. Moreover, as expected brachial artery EDV was lower in the patients with diabetes, but a new finding was that a greater increase in insulin-mediated phosphorylation of eNOS ser1177 was associated with higher brachial EDV, consistent with the idea that abnormal insulinmediated eNOS regulation is associated with impaired endothelial function in type 2 diabetes. Perhaps a more intriguing finding was that co-incubating the insulin-treated cells from diabetics with a selective PKC inhibitor reversed the abnormal decrease in insulin-stimulated phosphorylation of eNOS Ser1177 but had no effect on phosphorylation of inhibitory eNOS Thr495 in diabetics. Consistent with animal models of insulin resistance and cultured endothelial cells exposed to experimental high-glucose, 4 these data support the notion that enhanced PKC activity negatively modulates eNOS regulation in the human diabetic endothelium.
Interestingly, endothelial cells exposed to high glucose in vitro also demonstrate enhanced activity of nuclear factor kappa B (NF B), a key proinflammatory transcription factor that regulates hundreds of inflammatory genes, and is attenuated after PKC blockade. 13 Consistent with these in vitro findings, the study by Tabit et al. 11 report that endothelial cells from diabetic patients compared with control subjects, demonstrate a trend for higher expression of NF B p65 and intracellular adhesion molecule-1 (ICAM-1), and reduced expression of the inhibitor protein of NF B (I B ). This is significant because ICAM-1 is responsible for leukocyte adhesion to the endothelium during the early stages of atherosclerosis and endothelial dysfunction. Indeed, endothelial cells exposed to high glucose in vitro demonstrate a rapid increase in NF B activation 6 and increased expression of a variety of proinflammatory molecules that can be attenuated by PKC or NF B blockade. 14 One such "old" drug is metformin which is already widely used in patients with type 2
diabetes. In addition to its established effects on glycemic control, metformin also inhibits PKCand NF B signaling in glucose-and cytokine-exposed endothelial cells suggesting a mechanism to explain metformin's clinical benefits not attributable to glucose control. 15 Nonacetylated salicylates such as salsalate have gained interest in recent years in type diabetes because they have been shown to inhibit NF B activation in cytokine-stimulated endothelial cells, 16 increase insulin sensitivity of muscle and liver in obese/insulin resistant rodents 17 , improve glycemic control in humans with diabetes 18 and restore endothelial function in older obese adults. 19 Although salsalate's effects on PKC are unknown, in vitro and in vivo studies strongly implicate NF B in mediating endothelial insulin resistance in hyperglycemia. 6 Moreover, a recent elegant study demonstrates that functional NF B inhibition in transgenic rodents has a profound influence in the prevention of endothelial and systemic insulin resistance in diet-and genetic-induced obesity. 20 Taken together, these studies support the general concept that targeted NF B inhibition may be a new but logical approach to treat endothelial insulin resistance and dysfunction in humans with type 2 diabetes.
In summary, the study by Tabit et al. 11 
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